

Vinyl Chloride Financial Statement
November 30, 1981
Phase VIII - 19 Companies

Total Invoiced: \$303,000
Total Received: \$146,295
Date Phase Began: June 1, 1980

<u>Service/Program Category</u>	<u>Budget Authorized</u>	<u>Amount Committed</u>	<u>Disbursement</u>	<u>Unpaid Balance</u>	<u>Available for Commitment</u>
<u>RESEARCH</u>					
5-Year Epidemiology Update - EHA	\$220,000	\$-0-	\$-0-	\$-0-	\$220,000
<u>ADMINISTRATION</u>	\$ 35,000	\$ 35,000			
Direct Charges			\$15,084		
Travel			1,326		
Miscellaneous			231		
Subtotal Administration	\$ 35,000	\$ 35,000	\$ 16,641	\$18,359	\$-0-
<u>CONTINGENCY</u>	\$ 48,000	\$-0-	\$-0-	\$-0-	\$ 48,000
 TOTAL Phase VIII	 \$303,000	 \$ 35,000	 \$ 16,641	 \$ 18,359	 \$268,000

VINYL CHLORIDE FINANCIAL STATEMENT - SUMMARY SHEET
PERIOD ENDING 11-30-81
PHASES I thru VIII

PHASE	START DATE	CLOSE DATE	TOTAL RECEIVED INCLUDING CARRYOVER	AUTHORIZED BUDGET	PHASE COMMITMENTS				TOTAL PHASE COMMITMENT	TOTAL DISBURSED	UNPAID BALANCE ON COMMITMENT	CARRYOVER TO PHASE I	PANEL	MANAGEMENT
					ADMINISTRATION	RESEARCH	CONTINGENCY OR OTHER	REFUND						
I	2-8-72	2-22-79	\$144,517	\$144,395	\$ 8,901	\$114,095	\$ -0-	\$ 93	\$141,089	\$ 141,089	\$ -0-	IV	\$ 1,440	\$ -0-
II	2-8-72	OPEN	240,281 110,000*	239,949	45,976	193,971	-0-	110,000	239,949	343,794	6,355		-0-	-0-
III	6-5-74	12-19-75	251,240	251,240	13,700	224,090	-0-	642	230,432	230,432		V	12,800	-0-
IV	8-11-76	12-20-77	196,040	201,245	4,277	191,771	-0-		196,040	196,040				
V	8-11-76	7-12-77	124,318	127,800	4,600	115,000	-0-	790	120,390	120,390		VI	3,920	-0-
VI	12-30-77	8-1-79	301,349	297,418	11,250	252,020	-0-		264,078	264,078		VII	17,271	-0-
VII	5-12-79	OPEN	339,400	325,055	37,271	287,784	-0-		325,055	290,357	34,698		-0-	-0-
VIII	6-1-80	OPEN	146,295**	303,000	35,000	-0-	OPEN		35,000	16,441	18,359		260,000	-0-
TOTAL ALL PHASES			\$1,847,556	\$1,890,110	\$160,983	\$1,399,533	\$-0-	\$113,525	\$1,604,503	\$1,612,029	\$59,212	\$55,455	\$260,000	-0-
TOTAL MINORITY CARRYOVER			\$1,792,101					\$1,527						

*Refund from INT: Refunded, based on pro-rata share, to participating companies
**Funds in support of Phase VIII received to date

PHASE	RESEARCH ORGANIZATION
I	Yabershaw/Cooper Associates, Inc./Equitable Environmental Health, Inc.
II	Industrial Bio-Test Laboratories, Inc./Bob West Associates, Inc./Experimental Pathology Laboratories, Inc.
III	Dow Chemical U.S.A.
IV	University of Louisville (First Year)
V	Dow Chemical U.S.A.
VI	University of Louisville (Second Year)
VII	University of Louisville
VIII	5-Year Epidemiology Update